Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. - Wikidata - awgldk - TriplyDB

Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.

Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.

http://www.wikidata.org/entity/Q33633409

about

Targeted therapy of gastrointestinal stromal tumours Targeting gastrointestinal stromal tumors: the role of regorafenib Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications.Early outcomes of exon 11 mutants in GIST treated with standard dose Imatinib.Extragastrointestinal stromal tumour of the lesser omentum: A case report and literature review.Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review.Practical aspects of risk assessment in gastrointestinal stromal tumors.Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines Association of high expression of Groβ with clinical and pathological characteristics of unfavorable prognosis in gastrointestinal stromal tumors.Gastrointestinal Stromal Tumors (GIST): A Prospective Analysis and an Update on Biomarkers and Current Treatment Concepts.Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion.SLITRK3 expression correlation to gastrointestinal stromal tumor risk rating and prognosis Additional Primary Malignancies in Patients with Gastrointestinal Stromal Tumor (GIST): A Clinicopathologic Study of 260 Patients with Molecular Analysis and Review of the Literature.Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K)State of the Art in the Treatment of Gastrointestinal Stromal Tumors.Gene expression identifies heterogeneity of metastatic behavior among gastrointestinal stromal tumors.Expression and mutation of c-Kit in intracranial germ cell tumors: A single-centre retrospective study of 30 cases in China.Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor.How best to manage gastrointestinal stromal tumor.Gastrointestinal stromal tumors: who should get imatinib and for how long?Managing GIST in the imatinib era: optimization of adjuvant therapy.Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.The Role of Surgery in Metastatic Gastrointestinal Stromal Tumors.Get the GIST? An overview of gastrointestinal stromal tumours.Principles of Kinase Inhibitor Therapy for Solid Tumors.Small Bowel Neoplasms and Polyps.Sarcomas Associated With Genetic Cancer Predisposition Syndromes: A Review.Using molecular diagnostic testing to personalize the treatment of patients with gastrointestinal stromal tumors.Prognostic significance of KIT exon 11 deletion mutation in intermediate-risk gastrointestinal stromal tumor.Outcomes of adjuvant epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment for EGFR-mutant non-small-cell lung cancer: a propensity-score analysis.Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach.Cyclin-Dependent Kinase Activity Correlates with the Prognosis of Patients Who Have Gastrointestinal Stromal Tumors.Recent advances in managing gastrointestinal stromal tumor.Blood-Based Biomarkers Are Associated with Disease Recurrence and Survival in Gastrointestinal Stroma Tumor Patients after Surgical Resection.Liquid biopsy in gastrointestinal stromal tumors: a novel approach.Adjuvant imatinib for GIST: the pie is shrinking.Response to sunitinib of a gastrointestinal stromal tumor with a rare exon 12 PDGFRA mutation.Adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors: a retrospective cohort study.Disease-free survival improved by use of adjuvant EGFR tyrosine kinase inhibitors in resectable non-small cell lung cancer: an updated meta-analysis.

P2860

Q26745633-41409E69-7F0E-4706-BF1C-D3AFB0390CEB Q26747162-9FEFAA78-82B0-47D9-9FCA-7E601E52CF12 Q30245586-CC3A3192-3075-41B0-90A4-B95031F02F3A Q33575310-E06FAA0A-F220-45F6-8879-17ACDE09BA87 Q33806925-1DE44A69-1DC0-4652-8F4E-A81354AE5F94 Q33895608-CAA79919-5540-47CE-8428-BC5567CB86B8 Q34021413-ADCAB5C4-288F-4CD3-B6D2-16514356D90E Q34662946-5A2100C7-497C-4E69-BCC3-898E2ABDFC47 Q34672344-DBC8392A-A7B5-4358-B50B-962705A21601 Q35511907-5A33F4FD-027C-483E-A2A2-7A12633D257C Q35679349-18EF8286-BACD-4C1F-88A7-21B407A7CAAB Q35820539-EC4A4A5A-E835-455C-B9EF-24B428008EE2 Q35865274-30E79CAF-A31F-4A5C-9DE8-6B7BF11A9A11 Q35868168-9ED91BA9-A4D7-466B-AAFD-71FBA5FC57B0 Q35994305-B207DDDD-191B-48AB-ABDC-148E2AFE3A42 Q36344557-7AC6918B-F99B-41FE-BF7C-E34514C2AE59 Q36577759-F549C2E8-F69E-42A1-A513-69D2C764B467 Q36824624-B0EB4D94-F0AD-462F-BE75-3D38AEFBB5B4 Q37705793-47727BAF-1B89-4CBE-BC1F-A31047DDA80A Q37743051-B7501D8C-4F84-4B26-AF62-5CB85EDAF9FA Q38257940-1DAE8415-D428-4A38-8729-677AC0E9E688 Q38262193-B2484607-B935-4A63-8F94-2A507FB0E148 Q38379092-BB6A3F0A-F227-4A8B-B4C2-408A17A0AC3C Q38714790-1C0CBA68-7071-4B29-BD6A-E7FCDE4CE641 Q38718860-C8FC5F0A-B264-4FAD-9FA1-99EF9A712ABD Q38802154-2829254D-FB57-4647-95B4-F11282FD4E8E Q38810116-17195B31-D6F3-47CB-890B-1DCF3A5C79B8 Q38893082-0D464571-F94F-488D-B7D8-8D1BD3D8F03C Q39186932-73A4AAAF-5621-414B-9FE0-16A13831D5B2 Q39278610-0937517B-F5FC-4DC1-A379-62E0C9CBCDF8 Q41047277-9EE3D15C-7735-4DD7-99EB-477CA752A23A Q41078856-6E676463-3D2A-48E2-974F-E8B96487D6F4 Q41365125-78B00660-D331-4077-B091-5D400EBCEAD2 Q41725812-9D57462E-1699-44E7-A1DC-DE651CC38A9B Q41812070-CB8784BA-8B52-4953-9AE5-F9E7A87193AE Q42560645-EE063841-AEDD-4ED5-B48D-0B3DA15DBFD7 Q43141579-EF5683F6-7B07-4AD9-BCB5-DC30EFA748DA Q43243489-B37F2F04-F31C-4EF3-81B8-1258693D4B0A Q47103057-24A84F29-83FA-4A4A-849F-7FDA18BDDF25 Q47224555-2BA15A47-3BBF-498B-A417-0C06B38BC56A

P2860

Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.

http://www.wikidata.org/entity/Q33633409

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Pathologic and molecular featu ...... tumor: the ACOSOG Z9001 trial.

@ast

Pathologic and molecular featu ...... tumor: the ACOSOG Z9001 trial.

@en

type

label

Pathologic and molecular featu ...... tumor: the ACOSOG Z9001 trial.

@ast

Pathologic and molecular featu ...... tumor: the ACOSOG Z9001 trial.

@en

prefLabel

Pathologic and molecular featu ...... tumor: the ACOSOG Z9001 trial.

@ast

Pathologic and molecular featu ...... tumor: the ACOSOG Z9001 trial.

@en

P1433

Q33633409-A847F7A3-899A-48E1-9E88-9D89BED91695

P1476

Q33633409-80A393F8-7EBF-4800-9378-E45BD3A3D675

P2093

Q33633409-046D3574-0C8D-4BE1-8BDB-998C424F1CC5

Q33633409-0B742975-DE0D-4096-BE7A-A1CD363BE4A2

Q33633409-0BBA2519-81C7-4C8F-8A82-D40A6E2D3D2D

Q33633409-0D7A9769-D7BF-4DE1-8C77-E2A4103658A7

Q33633409-0FCD0D92-092B-4EF2-8A2C-C5585D6AD9D2

Q33633409-1080C48C-744F-4C17-9D60-9A3B4947C39F

Q33633409-120FA913-AC15-4F21-91F2-032990C39A51

Q33633409-55FF5164-AFFD-4688-ACC1-A6B897309CAB

Q33633409-70E8421A-F2EA-421B-A6B9-E626917C62C3

Q33633409-98B85196-C11C-4EF8-8D02-414CE18319D3

P2860

Q33633409-0FCFF570-EA64-4ED1-B915-B63AD56530CB

Q33633409-1CF6FF0B-89E0-437B-9D36-1ABE6FA18705

Q33633409-1E9D86A3-7BC4-4AB6-8514-11A3B90246AF

Q33633409-233C4503-5069-4317-B38A-35CC474E1AE2

Q33633409-2936B10F-E692-472E-A347-5FA0105ADF3C

Q33633409-2AC4B0FB-8848-4EF0-B3F4-C4D24303D8EF

Q33633409-35FA9795-287D-4D92-8DBC-E80EE8826BD5

Q33633409-37390CE1-630A-46F8-9A40-837666E10EB5

Q33633409-44BC8E91-C9BD-4525-BD3A-E6504B0A9F37

Q33633409-4C085055-AC57-4EE2-B57F-AF91D6E17E98

P304

Q33633409-A4B086EC-480C-4CF2-B068-1A8951D2E3BB

P31

Q33633409-F2618BEF-66ED-46E5-8D36-DEC6A283FE03

P356

Q33633409-2C8F0A84-45EE-48ED-B236-F219F9350973

P407

Q33633409-DB987A58-CFAE-4A43-8875-E7EF76ADFBC9

P433

Q33633409-B28FD6BE-887E-47B9-9942-F4E78704234E

P478

Q33633409-9C17DEB8-7859-44CD-9510-30E4817D5F99

P50

Q33633409-AECE7BA9-4AED-4C4F-B486-F8A84B016113

Q33633409-B25C1AF2-92EE-488A-A43E-61D5E419216E

P577

Q33633409-B0B8BCCD-1F6F-46B4-AC5C-FEAE2E7AA43A

P698

Q33633409-D859B43A-4741-46FE-BC9F-C6DCD14B9F0D

P932

Q33633409-FDE1A5F6-BF31-47E0-AF42-A7E1CEFCEC05

P356

JCO.2013.51.2046

P1433

Journal of Clinical Oncology

P1476

Pathologic and molecular featu ...... tumor: the ACOSOG Z9001 trial

@en

P2093

Charles D Blanke

http://www.w3.org/2001/XMLSchema#string

Christopher L Corless

http://www.w3.org/2001/XMLSchema#string

Cristina R Antonescu

http://www.w3.org/2001/XMLSchema#string

George D Demetri

http://www.w3.org/2001/XMLSchema#string

Karla V Ballman

http://www.w3.org/2001/XMLSchema#string

Kouros Owzar

http://www.w3.org/2001/XMLSchema#string

Margaret von Mehren

http://www.w3.org/2001/XMLSchema#string

Martin D McCarter

http://www.w3.org/2001/XMLSchema#string

Martin E Blackstein

http://www.w3.org/2001/XMLSchema#string

Peter W T Pisters

http://www.w3.org/2001/XMLSchema#string

P2860

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients.

Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

SDHA loss of function mutations in a subset of young adult wild-type gastrointestinal stromal tumors

Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations.

Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up.

P304

1563-1570

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2013.51.2046

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

Michael C. Heinrich

P577

2014-03-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24638003

http://www.w3.org/2001/XMLSchema#string

P932

4026579

http://www.w3.org/2001/XMLSchema#string